Ribavirin plasma levels were measured at weeks 1, 2, 4, 8, 12 and 24; ribavirin area under the concentration vs. time curve (AUC) was calculated using the linear trapezoidal rule.
INTRODUCTION
Less than 50 % of patients infected with hepatitis C virus (HCV) genotype 1 experience a sustained virologic response (SVR) following treatment with peginterferon plus ribavirin ( 1, 2 ) . Compared with Caucasian Americans (CA), SVR is signifi cantly lower in African Americans (AA) with HCV genotype 1 infections (19 -28 % vs. 52 % ) ( 3, 4 ) . However, the racial disparity in response is manifested 1 -2 days aft er treatment initiation as a weaker decline in serum HCV RNA in AA ( 5, 6 ) . A single-nucleotide polymorphism (SNP) near the interleukin-28B (IL28B) gene locus on chromosome 19q13.3 explains up to 50 % of the racial disparity in SVR ( 7 ) . Th e basis for residual disparity in peginterferon and ribavirin effi cacy has not been fully defi ned. An HCV NS3 protease inhibitor (boceprevir or telaprevir) combined with peginterferon and ribavirin is now standard therapy for HCV genotype 1 ( 8, 9 ). Yet, HCV protease inhibitors are also less effi cacious in AA ( 8, 9 ) . Th e exact cause is unclear, but racial diff erences in responsiveness to peginterferon and ribavirin are thought to have a role.
Th e likelihood of a SVR following peginterferon and ribavirin treatment is closely related to adherence to both drugs. In a similar way, higher peginterferon and ribavirin blood concentrations Optimum Ribavirin Exposure Overcomes Racial Disparity in Effi cacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1 have been associated with superior SVR rates ( 10 -16 ) . Peginterferon pharmacokinetics did not diff er between AA and CA in the study of viral resistance to antiviral therapy for chronic hepatitis C (VIRAHEP-C) ( 11 ) . In the Weight-based Dosing of Peginterferon alfa-2b and Ribavirin study, weight-based ribavirin dosing resulted in similar SVR rates (45, 42, and 47 % ) in CA patients weighing 65 -85 kg (1,000 mg), 85 -105 kg (1,200 mg) , and >105 -125 kg (1,400 mg), respectively ( 17 ) . Th e corresponding SVR rates in AA were 13, 22 , and 31 % ( P = 0.036), raising the possibility that standard weight-based ribavirin dosing is not optimum for many AA. Regarding ribavirin pharmacokinetics, a recent study reported a lower maximum plasma concentration and a borderline decrease in exposure (area under concentration vs. time curve, AUC) from time 0 to 12 h aft er the fi rst dose, and trends toward lower maximum plasma concentration and AUC levels aft er the week-8 dose in AA compared with CA ( 18 ) . Th e results were limited by a small sample size, and their clinical relevance was not assessed.
Th e current study investigated the relationship between ribavirin drug exposure (AUC) from week 1 to 24 and week 24 (WK24VR) and 72 (SVR) responses in AA and CA patients with HCV genotype 1 who were more than 90 % adherent to both peginterferon and ribavirin in the VIRAHEP-C. Also, we defi ned the significance of ribavirin exposure to treatment outcomes in relation to IL28B gene-related SNP rs12979860 and early HCV RNA kinetics (day 0 -28) ( 6,7 ).
METHODS

Patients and study design
In the VIRAHEP-C study ( 4 ), 401 treatment-naive adults (196 AA and 205 CA) with HCV genotype 1 infections were treated with peginterferon alfa-2a (180 μ g per week) and weight-based ribavirin 1,000 mg ( < 75 kg) or 1,200 mg ( ≥ 75 kg) for up to 48 weeks. Patient race was self-reported. Adherence to peginterferon and ribavirin treatment was measured with an electronic Medication Event Management System (MEMS) (Aardex, Zug, Switzerland). On the basis of MEMS, a similar percentage (80 -87 % ) of AA and CA patients received ≥ 80 % of the maximum peginterferon dose from week 1 to 24 during the VIRAHEP-C ( 4 ). In contrast, 76 % of CA and 56 % of AA received ≥ 80 % of the maximum ribavirin dose ( 4 ) . To avoid the racial diff erence in ribavirin drug adherence, we conducted a retrospective study in 150 consecutive VIRAHEP-C participants (75 AA and 75 CA) who received at least 95 % of the prescribed ribavirin dose during the fi rst 4 weeks and at least 80 % of the maximum doses of ribavirin and peginterferon during the fi rst 24 weeks. Four AA and two CA patients who received >120 % of the maximum ribavirin dose were excluded. Th e protocol and consent form were approved by the institutional review boards of the participating institutions. All patients provided informed written consent for the clinical trial; 114 of the 144 subjects consented to genetics studies.
Ribavirin plasma concentrations at weeks 1, 2, 4, 8, 12, and 24 were measured using a modifi cation of Liu ' s high-performance liquid chromatography with tandem mass spectrometry (LC-MS / MS) method ( 19, 20 ) . Ribavirin and an internal standard (5-methyl-2 ′ -deoxycytidine) were extracted with acetonitrile / ethyl acetate. An AQUASIL C18 reverse phase column with an isocratic mobile phase was used to separate ribavirin and the internal standard from the plasma matrix. Th e detection was accomplished using an API 3000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) with positive electrospray ionization. Ribavirin ( m / z 245 -113) and 5-methyl-2 ′ -deoxycytidine ( m / z 242 -126) transitions were assessed by multiple reaction monitoring. Th e assay was validated for ribavirin plasma concentrations of 20 -5,000 ng / ml. Cumulative ribavirin exposure (AUC) at intervals from day 0 to weeks 1, 2, 4, 8, 12, and 24 were calculated using the linear trapezoidal rule ( 11 ) .
Virologic end points
WK24VR and SVR (week 72), defi ned as an undetected serum HCV RNA ( < 50 IU / ml; Amplicor assay; Roche Molecular Diagnostics, Alameda, CA) were the primary virologic end points. Serum HCV RNA kinetics from day 0 to 28 were also studied. HCV RNA concentrations were measured on days 0, 1, 2, 7, 14, and 28 using the COBAS Amplicor Hepatitis C Virus Monitor Test, version 2.0 assay (sensitivity 600 IU / ml; Roche Molecular Diagnostics). Early viral kinetics phase 1 was defi ned as the difference in HCV RNA concentration (log 10 IU / ml) from day 0 to 1 and day 0 to 2 ( 5 ). Phase 2 was defi ned as the change in HCV RNA concentrations from day 7 to 28.
IL28B SNP rs12979860 genotyping
Genomic DNA samples (68 AA and 66 CA) were analyzed for SNP rs12979860 at the University of Maryland and Duke University using the TaqMan SNP Genotyping Assays (Applied Biosystems) ( 6, 21 ) . Replicate genotyping in 8 % of the samples was >98 % concordant.
Statistical analysis
Continuous variables were compared using t -tests, analysis of variance tests or nonparametric Wilcoxon rank-sum test as appropriate. Categorical variables were compared with chi-square ( χ 2 ) tests. Sixty-four patients per group provided 80 % power to detect a 20 % diff erence in ribavirin AUC between AA and CA with the 40 % interpatient variability observed. Th e eff ect of SNP rs12979860 genotype on virologic response was evaluated under the additive genetic model, with the genotype variable coded as the number of C alleles ( 6 ) . Logistic regression analysis was used to investigate the associations among baseline variables, ribavirin plasma exposure and virologic response. Variables that diff ered between AA and CA or between WK24 responders (WK24VR) and nonresponders (WK24NR) in univariate analysis ( P value ≤ 0.25) were retained for selection by the least absolute shrinkage and selection operator (LASSO) method ( 22 ) . Variables with non-zero coefficients were further analyzed in a multivariable logistic regression model. Receiver-operating characteristic curve (ROC) analysis was used to identify ribavirin AUC 0 − 7 thresholds or best cutoff levels to discriminate WK24VR and SVR from nonresponders. LASSO was performed using the R package lasso2. All other
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RESULTS
Patient characteristics
AA patients had a lower mean blood hemoglobin, serum ALT, and total serum bilirubin, and less hepatic steatosis in pretreatment liver biopsies than CA patients ( Table 1 ) ( 4 ). Mean serum creatinine was higher in AA, but creatinine clearance did not diff er between AA and CA . Th e IL28B SNP (rs12979860) C / C genotype was more frequent in CA; non-C / C (i.e. C / T and T / T) genotypes were more frequent in AA ( 7 ) . Mean adherence to both peginterferon and ribavirin from week 1 to 24 by AA and CA exceeded 90 % . Yet, week 4, 12, 24, 48, and 72 (SVR) response rates were lower in AA ( 4 ) . Similar to an earlier study of 361 VIRAHEP-C study participants (188 CA and 173 AA), CA with the SNP C / C genotype had higher WK24VR (C / C: 93 % ; C / T: 70 % ; T / T: 50 % ; P = 0.005) and SVR (C / C: 71 % ; C / T: 52 % ; T / T: 37 % ; P = 0.05) rates than CA patients with non-C / C genotypes ( 6 ) . Neither WK24VR (C / C: 78 % ; C / T: 60 % ; T / T: 47 % ; P = 0.13) nor SVR (C / C: 44 % ; C / T: 40 % ; T / T: 32 % ; P = 0.5) diff ered by SNP genotype in AA ( 6 ) . ( Table 3 ) . Similarly, AA patients with a SVR had higher ribavirin plasma concentrations at weeks 1 and 2 ( Figure 2c ) and greater ribavirin exposure ( Supplementary Table S1 online) at weeks 0 -1 ( P = 0.01), 0 -2 ( P = 0.02), and 0 -4 ( P = 0.08) than those without a SVR. In contrast, ribavirin plasma concentrations and exposure levels did not diff er by WK24VR ( Figure 2b ; Table 3 ) and SVR in CA ( Figure 2d ; Supplementary Table S1 online). Ribavirin plasma concentrations and exposure levels also did not diff er between AA and CA with a WK24VR ( Table 3 ) and SVR ( Supplementary Table S1 online). In contrast, AA with a WK24NR ( Table 3 ) had lower ribavirin concentrations and exposures than CA with a WK24NR at each time point . Among patients without a SVR ( Supplementary Table S1 online), the AA patients had lower ribavirin plasma concentrations at weeks 1 ( P = 0.006) and 2 ( P = 0.05), and less exposure at weeks 0 -1 ( P = 0.006), 0 -2 ( P = 0.01), 0 -4 ( P = 0.03), and 0 -8 ( P = 0.07).
Variables associated with ribavirin AUC 0 − 7 , WK24VR and SVR
Baseline patient characteristics associated with WK24VR, SVR, and ribavirin exposure (AUC) were identifi ed using multivariable regression analysis; 37 baseline variables that diff ered between AA and CA or between WK24VR and WK24NR in univariate analyses ( P ≤ 0.25) ( Tables 1 and 2 , Figures 1 and 2 ; Supplementary Table S2 online) were studied. Ribavirin AUC 0 − 7 ( P = 0.0008), IL28B SNP genotype C / C (vs. non-C / C) (odds ratio, OR: 9.0; 95 % confi dence interval (95 % CI): 2.5 -32.3; P = 0.0008), age ( P = 0.03), platelet count (OR: 1.01; 95 % : CI 1.001 -1.015; P = 0.03) and an interaction between AUC 0 − 7 and age ( P = 0.0017) were associated with WK24VR. Ribavirin AUC 0 − 7 , IL28B SNP genotype C / C, age, platelet count and an interaction between AUC 0 − 7 and platelet count predicted SVR. Patient race ( P < 0.003) was the only variable associated with ribavirin AUC 0 − 7 . 
Ribavirin
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Ribavirin Plasma Levels and SVR in African Americans from day 0 to 28 ( Figure 5a ) ( 6,23 -25 ) . Th e decline in HCV RNA from day 0 to 2 (phase 1) is thought to indicate interferon alpha ' s eff ectiveness at blocking HCV replication. Phase 2 (day 7 -28) is hypothesized to refl ect both interferon eff ectiveness and clearance of HCV-infected cells, and is a strong predictor of SVR. Th e fall in HCV RNA on day 1 and 2 (phase 1) did not diff er between AA and CA, but AA had lesser declines on days 7, 14, and 28 (phase 2) ( Figure 5a ). In a prior study, ribavirin had no eff ect on phase 1 kinetics when combined with peginterferon alfa compared with peginterferon alone. Instead, ribavirin appeared to prevent an increase (rebound) in HCV RNA from day 2 to 7 and to accelerate the fall in HCV RNA from day 7 to 28 (phase 2) when added to peginterferon ( 26 ) . Incidentally, AA with subthreshold ribavirin AUC 0 − 7 ( < 4,095 ng / ml × day) ( Figure 5b ) exhibited a 0.2 log10 IU / ml rebound in HCV RNA from day 2 to 7. By comparison, AA with threshold ribavirin AUC 0 − 7 ( ≥ 4,095 ng / ml × day) experienced a 0.2 log10 IU / ml decline in HCV RNA from day 2 to 7 ( P = 0.016) and greater falls in HCV RNA on days 7 ( P = 0.01), 14 ( P = 0.01), and 28 ( P = 0.07) ( Figure 5b ). Early HCV RNA kinetics did not diff er by ribavirin AUC 0 − 7 threshold in CA patients. Furthermore, the AA and CA patients with threshold ribavirin AUC had similar HCV RNA kinetics ( Figure 5b ). Stratifi ed by IL28B SNP genotype, the decline in HCV RNA from day 0 to 28 did not vary by ribavirin AUC 0 − 7 category in the AA ( Figure 5c ) and CA patients ( Supplementary Figure S3A online) with CC genotypes. Indeed, AA with subthreshold ribavirin AUC 0 − 7 had greater declines in HCV RNA on days 1 and 2 (phase 1) compared with AA with threshold ribavirin AUC 0 − 7 levels ( Figure 5c ), but experienced an HCV RNA rebound from day 2 to 7 and a comparable decline from day 7 to 28 (phase 2). HCV RNA kinetics from day 0 to 2 and day 2 to 7 did not vary by ribavirin AUC 0 − 7 category in AA with non-CC genotypes ( Figure 5d ). Yet, AA with threshold levels exhibited a greater fall in HCV RNA from day 7 to 28 ( Figure 5d ). Among CA with non-CC, those with subthreshold AUC 0 − 7 had greater declines in HCV RNA on days 1 and 2, but experienced an HCV RNA rebound from day 2 to 7 and equivalent log10 declines from day 7 to 28 ( Supplementary Figure S3B online) .
Figure S2 online). Th us, the specifi ed ribavirin exposure thres holds were better at discriminating responders from nonresponders among AA.
A ribavirin AUC 0 − 7 ≥ 4,095 was associated with a higher WK24VR in the total sample, and in both AA and CA subgroups ( Figure 3a ). An AUC 0 − 7 ≥ 4,480 was associated with a higher SVR overall, but only in AA when the races were analyzed separately ( Figure 4a ). Mean ribavirin exposure during week 1 did not diff er between AA and CA with a ribavirin AUC 0 − 7 ≥ 4,095 ng / ml × day (AA: 5,596 ± 1,033; CA: 5,920 ± 1,710 ; P = 0.32) and a ribavirin AUC 0 − 7 ≥ 4,480 ng / ml × day (AA: 5,770 ± 966, CA: 6,139 ± 1,703; P = 0.28). Among patients with subthreshold ribavirin AUC 0 − 7 levels, the AA patients had lower exposure than the CA patients (ribavirin AUC 0 − 7 < 4,095 ng / ml × day: AA: 2,728 ± 887, CA: 3,255 ± 668; P = 0.019; ribavirin AUC 0 − 7 < 4,480 ng / ml × day: AA: 2,879 ± 959, CA: 3,474 ± 729; P = 0.007). WK24VR ( Figure 3a ) and SVR ( Figure 4a ) rates did not diff er between AA and CA with threshold ribavirin AUC 0 − 7 levels. In patients with subthreshold ribavirin AUC 0 − 7 levels, on the other hand, the AA patients had lower WK24VR ( P = 0.07) and SVR ( P = 0.02) rates compared with the CA patients. Using race-specifi c ribavirin AUC 0 − 7 thresholds for WK24VR (AA ≥ 4,060; CA ≥ 4,585) and SVR (AA ≥ 4,375; CA ≥ 4,935) did not change the results (data not shown).
WK24VR ( Figure 3b ) and SVR ( Figure 4b ) rates did not differ by ribavirin AUC 0 − 7 category (i.e. threshold vs. subthreshold) in patients with the IL28B SNP C / C genotype, both overall and within the AA and CA subgroups. In contrast, a threshold ribavirin AUC 0 − 7 level was associated with higher WK24VR ( Figure 3c ) and SVR ( Figure 4c ) rates overall, and among AA patients with IL28B SNP non-CC genotypes. Similar trends were observed in the CA patients with non-C / C, but the diff erences were not signifi cant (possibly because of a small sample size). In addition, there were no racial diff erences in WK24VR ( Figure 3b,c ) and SVR ( Figure  4b,c ) rates among patients in the same ribavirin AUC 0 − 7 and IL28B SNP genotype categories.
Ribavirin exposure and early viral kinetics
Consistent with previous reports, responders to peginterferon plus ribavirin exhibited two distinct phases of HCV RNA decay 
DISCUSSION
In patients with HCV genotype 1 infections and exceptional adherence to weight-based ribavirin plus peginterferon treatment, the AA patients had lower ribavirin plasma exposure (AUC) from week 1 to 12, and were less likely to achieve ribavirin plasma exposure thresholds during the fi rst week (AUC 0 − 7 ) that predicted WK24VR and SVR. Remarkably, racial diff erences in WK24VR and SVR rates were eliminated in patients who reached these ribavirin AUC 0 − 7 thresholds. Ribavirin AUC 0 − 7 thresholds were associated with WK24VR and SVR independently of IL28B SNP genotype. However, achieving the . SVR for total sample ( a ) and patients with interleukin-28B (IL28B) single-nucleotide polymorphism (SNP) CC ( b ) and non-CC ( c ) genotypes stratifi ed by AUC 0 − 7 category and race. Response rates between ribavirin exposure categories were compared using the χ 2 tests.
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Ribavirin Plasma Levels and SVR in African Americans ( 14 -16 ) . Diff erences in ribavirin plasma concentrations (week 1 -4) and ribavirin AUC from week 1 to 12 between the AA and CA patients with similar drug adherence is a novel fi nding. Ribavirin accumulation was independently associated with patient age, body weight, body mass index, gender, initial ribavirin dose, and creatinine clearance in previous studies ( 12, 13 ) . AA had a higher estimated mean serum creatinine clearance and received a marginally lower ( P = 0.09) weight-normalized ribavirin dose. However, creatinine clearance did not diff er between AA and CA. In a multi variable regression model that included these variables, patient race was the only variable independently associated with ribavirin exposure during the fi rst treatment week. In a population pharmacokinetic model, the apparent peripheral volume of distribution for ribavirin was 1.5 times greater in the AA patients compared with the CA patients (Jin et al. ( 20 ) , accepted for publication). Th is probably explains the racial divergence in ribavirin plasma concentrations and exposure, though the underlying mechanism(s) is unknown. Up to 50 % of patients experience a decline in blood hemoglobin to < 12 g / dl during peginterferon combination therapy, because of hemolysis linked to ribavirin ' s dose and plasma concentration ( 12, 13, 27, 28 ) . Racial diff erences in hemoglobin kinetics in the present study correlated with variation in ribavirin exposure. Indeed, AA had a slower decline in blood hemoglobin from week 0 to 4 and a higher hemoglobin nadir during the fi rst 24 weeks, despite lower pretreatment hemoglobin. Previous studies have found higher ribavirin plasma concentrations and exposure (AUC) in patients with an SVR compared with non-SVR following peginterferon combination treatment ( 12 -16 ) . A ribavirin AUC 0 − 12hr > 3,014 ng / ml × h aft er the fi rst dose was associated with 12.5 greater odds for SVR relative to lower exposure levels in one study ( 16 ) . A ribavirin plasma concentration > 2,010 ng / ml at week 4 was optimum for SVR in patients with HCV genotype 1 in another ( 29 ) . In the present study, ribavirin exposure ≥ 4,095 and ≥ 4,480 ng / ml × day during the fi rst week (AUC 0 − 7 ) were thresholds for WK24VR and SVR, respectively. Sequential ribavirin plasma concentrations and ribavirin AUC levels (AUC 0 − 7, 0 − 14, 0 − 28 , etc.) were highly correlated ( r coeffi cient >0.95 each; P < 0.001); thus, the ribavirin concentration at the week 1 predicted the steady-state (week 8 -24) level. Patients who achieved the specifi ed ribavirin AUC 0 − 7 thresholds had higher WK24VR and SVR rates than those with subthreshold levels, with the biggest diff erences observed in AA patients. Th e AA patients were almost 50 % less likely to have a threshold ribavirin AUC 0 − 7 than the CA patients. Yet, WK24VR and SVR rates did not differ between AA and CA with threshold ribavirin AUC 0 − 7 . Among patients with subthreshold ribavirin AUC 0 − 7 levels, on the other hand, the AA patients had signifi cantly lower ribavirin AUC 0 − 7 levels and response rates. Th ese results indicate a racial diff erence in ribavirin pharmacokinetics (i.e. larger volume of distribution) is responsible for the lower WK24 and SVR to peginterferon and ribavirin treatment for HCV genotype 1 in AA compared to CA. It is noteworthy that ribavirin plasma concentrations and exposure varied by WK24VR and SVR only in the AA patients. Th is fi nding diff ers from previous studies, and may be explained by the specifi ed ribavirin exposure thresholds increased response rates preferentially in the AA patients with the less favorable IL28B non-CC genotypes. Th ese results provide important new insights into the basis for the racial disparity in treatment responses to peginterferon and ribavirin treatment for HCV genotype 1.
Consistent with prior studies, we found substantial variability in ribavirin plasma concentrations and cumulative ribavirin exposure (AUC), even in patients with >90 % medication adherence small number of AA in prior studies as well as diff erences in study designs. To avoid racial diff erences in ribavirin adherence reported in VIRAHEP-C ( 4 ), we selected patients who had received >90 % of the maximum doses of both medications from week 1 to 24. In contrast, previous studies included patients who received either < 80 % of the maximum weight-based ribavirin or an 800 mg (i.e., fl at) ribavirin dose ( 12, 13, 30 ) . IL28B gene-related SNP rs12979860 on chromosome 19 is strongly associated with response to peginterferon and ribavirin in US patients with HCV genotype 1 infections ( 7, 21 ) . Patients with the C / C genotype have more rapid declines in serum HCV RNA during the fi rst (day 0 -2) and second (day 7 -28) phases of early viral kinetics, and two-to three-fold higher response rates at weeks 4, 12, 24, 48, and 72 (SVR) than those with the non-C / C (i.e. T / T and C / T) genotypes ( 6, 21 ) . Th e C allele is much less frequent in AA than in CA, and this diff erence is estimated to explain > 50 % of the racial disparity in early viral kinetics (day 0 -28) and 30 -50 % of the disparity in SVR ( 6, 7, 21 ) . Th e present study shows that variability in ribavirin AUC 0 − 7 can explain much of the remaining diff erence between AA and CA in peginterferon and weight-based ribavirin treatment effi cacy for HCV genotype 1. Ribavirin AUC 0 − 7 , SNP genotype, age, and platelet count were associated with WK24VR and SVR in multivariable regression analysis. Controlling for these four variables, patient race did not predict WK24VR and SVR. Yet, achieving threshold ribavirin AUC 0 − 7 augmented WK24VR and SVR most signifi cantly in AA with IL28B SNP non-C / C genotypes. Compared with subthreshold ribavirin exposure, the benefi cial eff ect threshold ribavirin exposure in AA was associated with greater reductions in HCV RNA during early viral kinetic phase 2 (day 7 -28) that is known to predict SVR. Dixit et al. ( 31 ) proposed that the need for ribavirin during phase 2 is inversely correlated with interferon alpha ' s eff ectiveness or the vigor of the phase 1 response. Th us, higher interferon eff ectiveness in patients with the C / C geno type ( 6, 20 ) probably explains why phase 2 kinetics, WK24VR and SVR did not diff er by ribavirin AUC 0 − 7 in C / C patients.
Th is study has some limitations. Th e sample size provided adequate statistical power to detect diff erences in ribavirin exposure between AA and CA. However, fewer CA patients had suboptimum ribavirin exposure based on ROC analysis. Plus, small numbers of AA with C / C and CA with non-C / C genotypes were studied. As a result, statistical power was limited in some analyses of treatment responses by ribavirin AUC 0 − 7 thresholds in CA and in each race stratifi ed by IL28B SNP genotype. Th is might explain why WK24VR and SVR rates did not diff er by ribavirin AUC 0 − 7 threshold in CA with non-C / C. In addition, we studied patients with exceptional adherence to both peginterferon and ribavirin. Th us, a larger study with a full range of peginterferon and ribavirin adherence observed in the VIRAHEP-C would be required to completely defi ne the importance of ribavirin exposure to treatment outcomes in relation to IL28B SNP variation. Functional polymorphisms (rs1127354 and rs7270101) in the inosine triphosphatase ( ITPA ) gene on chromosome 20 were associated with the extent of decline of blood hemoglobin at week 4 in 304 VIRAHEP-C study participants (167 CA and 137 AA) ( 32 ) . Minor alleles (ITPA defi ciency) provided protection against anemia. However, the frequency of ITPA defi ciency was similar in CA and AA and did not predict SVR in the VIRAHEP-C ( 32 ). Lower serum interferon-gamma inducible protein 10 (IP10) levels ( < 600 pg / ml) pretreatment were associated with an increased SVR following peginterferon and ribavirin treatment for HCV genotype 1 in both AA ( n = 134) and CA ( n = 138) overall and stratifi ed by IL28B SNP genotypes in VIRAHEP-C ( 33 ). AA had higher pretreatment IP10 levels. However, variation in pretreatment IP-10 levels did not explain the racial diff erence in SVR ( 33 ) . Th us, we did not analyze these markers.
In conclusion, the present study shows that current weightbased ribavirin dosing guidelines result in suboptimal ribavirin plasma exposure for WK24VR and SVR during peginterferon plus ribavirin therapy in 60 % of AA and 36 % of CA patients with HCV genotype 1 infections and exceptional medication adherence. Th e racial diff erence in ribavirin exposure appears to be related to a larger volume of ribavirin distribution in AA ( 20 ) . Ironically, lower ribavirin exposure in AA was compounded by a higher frequency of IL28B SNP rs12979860 non-C / C genotypes that are associated with lower interferon eff ectiveness (phase 1) and a greater need for ribavirin during phase 2 of early viral kinetics. IL28B SNP non-C / C genotypes also predict a poorer response to HCVNS3 protease inhibitors combined with peginterferon and ribavirin, the new standard for HCV genotype 1 treatment ( 8, 9 ) . Future studies should determine the importance of ribavirin pharmacokinetic variability to racial disparities in treatment responses to HCVNS3 protease inhibitors and other directacting antiviral treatments for HCV .
